Contact us
Log in
Dr. Filippo Alongi


Radiation Oncologist and clinical investigator. Associate Professor in Radiation Oncology.

He published more than 230 scientific articles (indexed/ Peer reviewed Journals), 4 book chapters and more than 300 abstracts presented as oral presentation or posters at national and international scientific congress). His h-index is 29.

Main topics of his activity are: SBRT, hypofractionation, IGRT, molecular imaging in Radiation Oncology, prostate cancer, oligometastases.

From 2010 assistant and associate chief at Radiotherapy and Radiosurgery department Humanitas Cancer Center in Milan(Rozzano).

From 2012, He is the national coordinator of young group of AIRO(Italian society of Radiation Oncology) and he is in the board of AIRO prostate working group.

From 2014 he is member of AIRO National Scientific Committe.

He is member of "Technology in Cancer Research Treatment " and managing editor of “Radiation Oncology”

From 2014, He is Head of Radiation Oncology Department of Sacro Cuore-Don Calabria Cancer Care Center in Negrar(Verona ).

2015: Associate Professor professional qualification in Radiation Oncology

2017: Associate professor in Medicine, Brescia University. 

Verona, Italy
Radiation Oncology
English  /  Italian

Work Experience

Direttore di Dipartimento
Since 2019
Radioterapia Oncologica Avanzata, IRCCS Ospedale Sacro Cuore Don Calabria
Associate Professor Of Medicine
Since 2017
Università degli Studi di Brescia
Chair/Director of Department of Advanced Radiation Oncology
Since 2014


Laurea in medicina e chirurgia
Universita' di Palermo
Specializzazione in Radioterapia, Medicina
Universita' Milano-Bicocca
Abilitazione a Professore di II fascia (Radioterapia)


Feasibility and safety of 1.5 T MR-guided and daily adapted abdominal-pelvic SBRT for elderly cancer patients: geriatric assessment tools and preliminary patient-reported outcomes.
Journal of cancer research and clinical oncology Read it here 1.5 T MR-guided and daily adapted SBRT for prostate cancer: feasibility, preliminary clinical tolerability, quality of life and patient-reported outcomes during treatment.
Radiation oncology (London, England) Read it here Oligometastasis and local ablation in the era of systemic targeted and immunotherapy.
Radiation oncology (London, England) Read it here